Mesenchymal stem cells (MSCs) are strongly immunosuppressive in vivo and in vitro in both animals and humans. Using cloned MSCs from mouse bone marrow, we have shown that MSCs potently inhibit TCR-activated proliferation and cytokine production of freshly-isolated splenocytes. In vivo, MSCs prevented the rejection of allogeneic skin transplants, suppressed antigen-specific DTH responses, and inhibited graft-versus-host disease (GvHD) in mice. Interestingly, MSCs did not affect the IL-2-driven proliferation of T cell blasts, which do not produce inflammatory cytokines unless re-activated. The immunosuppressive effect of MSCs requires the co-presence of IFN3 and another cytokine - either TNF1, IL-11 or IL-12. Such cytokine pairs provoked MSCs to express inducible nitric oxide synthase (iNOS), produce NO, and secrete of large amounts of T cell specific-chemokines, which complement the activity of NO: in co-cultures, these chemokines drove T cells to migrate into proximity with MSCs, where high levels of NO can suppress T cells. Blockade of NO production or chemokine receptors reversed the inhibition of T cells. We recently found that while human MSCs are equally effective in suppressing T cells and have a similar spectrum of chemokine production, they utilize IDO to affect immunosuppression. Thus, we hypothesize that proinflammatory cytokines induce MSCs to produce chemokines and NO (in mouse) or IDO (in human) which act in concert to mediate immunosuppression. We propose two specific aims to prove this hypothesis using mouse and human MSCs to complement each other. We will first investigate the role of chemokines and NO or IDO in mediating immunosuppression of MSCs in both mouse cells and human cells in vitro and in the mouse GvHD model in vivo. Next, we will determine the molecular mechanisms of the regulation of IDO and NO in mouse and human MSC. Since MSC-mediated immunosuppression occurs through inflammatory cytokine-upregulation of iNOS/IDO and chemokines, a better understanding of the mechanisms underlying these effects will lead to better clinical protocols for immune disorders, cancer immunotherapy and vaccine design.

Public Health Relevance

One of the most important properties of mesenchymal stem cells is their high potency in suppressing immune reactions, which can be involved in many diseases such autoimmune disorders, allergic reactions, rejection of transplants and graft-versus-host disease associated with bone marrow transplantation. It is likely that the very first clinical application of stem cell research will be the use of mesenchymal stem cells to treat immune disorders. Therefore, the proposed studies are expected to have enormous relevance to human health.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
7R01GM866889-05
Application #
8721676
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Dunsmore, Sarah
Project Start
2010-02-10
Project End
2015-01-31
Budget Start
2013-07-01
Budget End
2015-01-31
Support Year
5
Fiscal Year
2013
Total Cost
$287,423
Indirect Cost
$106,654
Name
Rbhs-Robert Wood Johnson Medical School
Department
Type
DUNS #
078795875
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Ling, Weifang; Zhang, Jimin; Yuan, Zengrong et al. (2014) Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 74:1576-87
Chen, Qing; Shou, Peishun; Zhang, Liying et al. (2014) An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells. Stem Cells 32:327-37
Zhang, J; Roberts, A I; Liu, C et al. (2013) A novel subset of helper T cells promotes immune responses by secreting GM-CSF. Cell Death Differ 20:1731-41
Li, W; Ren, G; Huang, Y et al. (2012) Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 19:1505-13
Shi, Yufang; Su, Juanjuan; Roberts, Arthur I et al. (2012) How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 33:136-43